Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Sortiert nach
Open Access
    Datensatz exportieren als...
  • BibTeX
Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report
Case reports in oncology, 2024-01, Vol.17 (1), p.175-179
2024
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Cryptosporidiosis, an Uncommon Complication after Allogeneic Stem-Cell Transplantation
Case reports in oncology, 2023-08, Vol.16 (1), p.591-596
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
Cancer medicine (Malden, MA), 2020-09, Vol.9 (18), p.6565-6575
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Ciltacabtagene Autoleucel for Patients With Triple‐class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE‐1 Patient Outcomes Versus Real‐world Clinical Practice
HemaSphere, 2022-12, Vol.6 (12), p.e813-n/a
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3
HemaSphere, 2023-08, Vol.7 (S3), p.e1309654-n/a
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, 2023-09, Vol.29 (9), p.2259-2267
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Therapeutic recommendations for early stage Hodgkin lymphomas
British journal of haematology, 2019-01, Vol.184 (1), p.9-16
2019
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)
Blood, 2021-11, Vol.138 (Supplement 1), p.54-54
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Blood, 2019-11, Vol.134 (Supplement_1), p.5309-5309
2019
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5)
Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7591-TPS7591
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Unexpected Leishmania in a bone marrow aspirate
American journal of hematology, 2021-09, Vol.96 (9), p.1176-1177
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
ABCL-353 Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S474-S474
2024
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S216-S216
2024
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
ABCL-320 Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S372
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Poster: ABCL-320 Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S163
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma
Blood, 2021-11, Vol.138 (Supplement 1), p.4075-4075
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S439-S440
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
POSTER: ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S204-S204
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
P-286 Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3
Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S194-S194
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S170-S170
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Poster: ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results
Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S238-S238
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results
Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S392-S392
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients
Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S124-S124
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
7 - Treatments in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Real-World Outcomes for Standard of Care (SOC)
Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S6-S7
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Treatments in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Real-World Outcomes for Standard of Care (SOC)
Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S6-S7
2022
Volltextzugriff (PDF)
1 – 25 von 29
Suche als RSS-Feed
Suchergebnisse filtern
Filter anzeigen